Schedule an Appointment
S2G Biochemicals Inc.

S2G Biochemicals Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

Book a Conference Call
Get More Information

S2G Biochemicals Inc.

Location: Vancouver, British Columbia Sector: Life Science .
Add to Shortlist
Express Interest

s2G Biochemicals Inc. has developed the most sustainable and lowest cost technology to co-produce xylitol – a premium low-calorie sweetener – and biochemical glycols. Xylitol is a natural sweetener with the same sweetness quality as regular sugar, but 1/5 the glycemic index effect (1/5 the effect on blood sugar levels) and 40% less calories than regular sugar. It is safe for consumption by people who have intolerance to regular sugar for diabetic or dietary reasons. Valued for its excellent taste and oral health benefits, xylitol produced with S2G technology will enjoy strong growth in the multi-billion dollar low-calorie sweetener market.

Business Documents

MG cp Summary

Sustainable – Most sustainable production process technology:  High yield, no harsh chemicals and supports shift away from reliance on oil and gas.

 

Cost effective – Most cost-effective production methods- S2G technology makes xylitol at lowest cost while producing high value bio-glycols.

 

Valuable co-products – No other production methods produce viable quantities of valuable co-products; S2G produces bio-glycols which adds to overall returns for plants employing the S2G technology.

 

Non-GMO – S2G’s process for producing xylitol includes sources of feedstocks that are non-GMO – a feature of growing importance for consumers. S2G intends to only produce using non-GMO sources.

 

Pulp mill/biorefinery value-add – S2G’s process uses sustainable byproducts produced by various pulp mills and biorefineries from biomass (agriculture and forest residues).  These experienced operators are diligently looking for new sources of income to increase their revenues and add value to their current production. Presently they are unable to get more than heating value from the bioproducts of their pulping processes.  The S2G Xylitol process will increase byproduct value from ~$125/MT to ~$2000/MT.

S2G Biochemicals Inc. has developed the most sustainable and lowest cost technology to co-produce xylitol – a premium low-calorie sweetener – and biochemical glycols. Xylitol is a natural sweetener with the same sweetness quality as regular sugar, but 1/5 the glycemic index effect (1/5 the effect on blood sugar levels) and 40% less calories than regular sugar. It is safe for consumption by people who have intolerance to regular sugar for diabetic or dietary reasons. Valued for its excellent taste and oral health benefits, xylitol produced with S2G technology will enjoy strong growth in the multi-billion dollar low-calorie sweetener market.

Mark Kirby – President and CEO |  Mark is a chemical industry and cleantech Executive with a strong leadership, business developement, engineering, operations and product development background. He has attained success with both major multinational corporations and with technology start-up companies.

 

Jeff Plato – Director, Corporate and Project Development | Jeff has 30+ years of growth leadership in business unit, technology and services sales and marketing management. He bring extensive leadership , sales and marketing management experience in electronic, industrial and clean energy industries to S2G.

 

Himanshu Kamboj – CFO | A graduate of the University of British Columbia, Himanshu assumed roles accounting roles and management positions at Dale Matheson Carr-Hilton Labonte Chartered Accountants and MNP LLP before joining S2G where he heads the accounting, tax and finance departments. He also maintains investor relations and is in charge of audits.

 

Kent Smith – Director, Projects | Kent is a senior manager/executive/professional engineer with over 20 years of experience in port operations, maintenance, mining, procurement, logistics and business management. Prior to joining S2G biochemicals, Kent worked at SRK Engineering Limited, Pacific coast terminals co. and Vancouver Wharves Ltd.

 

Claudio Arato – Senior Engineer, Director, Process | Caludio lead the process team at S2G on $5.5MM pilot plant scale up and the development team on catalytic process of converting C3 and C5/C6 sugars to glycols.  Before S2G, Caludio worked in various capacities including CTO, Director of engineering and technology, and senior engineer in companies that include Provectus Engineered Materials, Sonoro Energy and Lignol Innovations.


Biopep Solutions Inc.

Biopep Solutions Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Biopep Solutions Inc.

Location: Richmond, British Columbia

Sector: Life Science

.

Add to Shortlist
Express Interest

Biopep Solutions Inc. is a private late-preclinical stage bio-tech company. Biopep’s lead candidate drug’s multivalent cancer inhibition mechanism is revolutionary in the treatment of cancer. The drug, called BPS-001, blocks the channels cancer tumors use to promote cancer survival  and their ability to grow and spread.  Rather than being limited to the short-comings of current drugs and therapies, Biopep believes that it is developing the next generation of cancer therapy that will simultaneously block the different channels of cancer growth.

Business Documents

MG cp Summary

Need for a drug that is effective against cancer resistance 

The problem with conventional drugs and therapies is that the cancer develops resistance to them over time and it returns in a more aggressive form.In comparison to the weaknesses of the current prostate cancer drugs, BPS-001 inhibits the expression of the entire androgen receptor as well as inhibiting the growth of new blood vessels, reducing inflammation and cancer cell migration, and activating cancer cell death.

 

Need for a cancer therapy with minimal side effects

Chemotherapy is toxic and has a negative impact on the quality of life for the patient. As well as being toxic, it is non-specific, meaning healthy cells are also affected. BPS-001 is non-toxic at over 160 times the normal dose in animal studies. As opposed to conventional cancer therapies, BPS-001 is administered weekly through an injection similar to insulin.

 

Need for effective late stage prostate cancer therapy

When caught early, prostate cancer is often treatable. However, the only option to advanced prostate cancer patients treatment is chemotherapy which is very toxic and only prolongs life.BPS-001 has the potential to change the landscape of cancer therapy by providing a more effective treatment of late stage metastatic prostate cancer (mCRPC) in comparison to existing drugs, without any significant toxic side effects, and durable treatment.

Biopep’s lead drug candidate, BPS-001, has a unique multivalent mechanism to treat various forms of cancer.  The initial target indication is prostate cancer.  However, unlike conventional therapies like chemotherapy, hormone depravation therapy or immunotherapy, BPS-001 has the following advantages:

  • A multivalent mechanism of action, which targets multiple pathways and sites on the cancer cell, which means the cancer will be unable to develop resistance to the treatment which is the case with conventional single targeted drugs;
  • Inhibits the formation of new blood vessels that feed the cancer (i.e. inhibits the process of angiogenesis);
  • Promotes the programmed death of cancer cells by a process called apoptosis;
  • Reduces inflammation which is a driver of all major diseases;
  • BPS-001 has very low toxicity giving it a large therapeutic window;
  • Ease of administration, a once weekly subcutaneous injection; and
  • BPS-001 has the potential to change the landscape of cancer therapy by providing a more effective treatment for late stage prostate cancer (mCRPC) in comparison to existing drugs and therapies.

Ahmed Merzouk, Director, President and Chief Executive Officer

Dr. Merzouk has more than 20 years’ experience in industry and academia in drug discovery of small and large molecules. The expertise of Dr. Merzouk ranges from design, synthesis, and purification of synthetic molecules to extraction of active ingredients from natural sources.

 

Yalcin Ilsever, PhD, CPA.CGA, IMA(USA),FICBDirector, Executive Vice President and Chief Financial Officer

Dr. Ilsever is a Chartered Professional Accountant (CPA). His PhD is in  Accounting, Finance and Statistical Measurement. He has extensive experience in the private sector in the issuance of fixed income securities and equities. Dr. Ilsever has also published extensively on electronic commerce platforms, and business measurement systems.

 

Gary Yalloway, PhD, Director, Vice President, Regulatory Affairs and Drug Development

Dr. Yalloway has over 22 years of multidisciplinary experience in industry and academia and skills in enzyme engineering and protein purification of proteins of medical and industrial interest. He has significant experience in regulatory affairs with both the US Food and Drug Administration and Health Canada. He is highly experienced in all aspects of R&D, process development, and the scale-up and manufacture of therapeutic proteins. His specialties include upstream and downstream processing, including large-scale production and bulk manufacturing of recombinant proteins.


Aquila Diagnostic Systems

Aquila Diagnostic Systems

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Aquila Diagnostic Systems Inc.

Location: Edmonton, Alberta

Sector: Life Science

.

Add to Shortlist
Express Interest

Aquila Diagnostic Systems Inc. is exploiting its patented molecular (DNA/RNA) diagnostic technology to provide a game-changing solution for the tangible and quantifiable pain caused by the poor state of diagnostics which currently exists in the large North American and European markets for companion animal (canine and feline), with plans to expand to the equine and food production markets including poultry, dairy and porcine.

Business Documents

MG cp Summary

Low cost technology – Ability to price Aquila products at same price as veterinarians pay today for an inferior product

 

Ability to work with any industry standard diagnostic instrument – Aquila is not building a diagnostic instrument: we are agnostic to instrument providing the customer with a wide variety of instrument options depending upon budget and requirements.

 

Patents on Aquila hydrogelStrong patents in place in a technology where such patents are extremely difficult to achieve

 

Ability to work with “dirty” samples – Aquila’s patented hydrogel provides a significant and sustainable competitive advantage with its unmatched ability to work with “dirty” samples such as milk and feces.

 

Simple or no DNA extraction required from sample – Minimizes or eliminates step when compared to conventional PCR technology. Lowers cost and time to perform test.

“ Aquila Diagnostic Systems Inc. is exploiting its patented molecular (DNA/RNA) diagnostic technology to provide a game-changing solution for the tangible and quantifiable pain caused by the poor state of diagnostics which currently exists in the large North American and European markets for companion animal (canine and feline), with plans to expand to the equine and food production markets including poultry, dairy and porcine.”

Brent James, CEO, B.Comm UBC; MBA Sloan School MIT

Brent James has a 30-year history of accomplishments in the high tech field including co-founding a company (MDSI) that went public on NASDAQ, and being the turn-around CEO of a company (Abebooks.com), which was sold to Amazon.

 

Dr. Jason Acker, Co-Founder & CTO; BSc, MSc, MBA, PhD

Dr.Jason Acker, Co-Founder and Chief Technology Officer, brings more than 15 years of experience with multinational pharmaceutical and biotechnology companies in Canada, USA, Singapore and the U.K.  Jason also managed interdisciplinary teams at the University of Alberta, Canadian Blood Services, and Harvard Medical School.

 

David Alton, Co-Founder & COO; MBA

David Alton co-Founder and Chief Operating Officer of Aquila, has extensive experience in the micro and nano technology sectors, research management and company start-ups

 


PlantForm Corporation

PlantForm Corporation

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

PlantForm Corporation

Location: Toronto, Ontario

Sector: Life Science

.

Add to Shortlist
Express Interest

PlantForm Corporation is a privately-held Canadian biopharmaceutical company, commercializing a plant-based manufacturing platform, vivoXPRESS®, for the low-cost production of high-value therapeutic drugs. Their pipeline includes biosimilar drugs with a focus on international markets including China, Europe, India, Latin America, MENA as well as major North American and European markets. The company is also developing innovator biologics for niche infectious disease and countermeasures-to-bioterrorism markets. Their pipeline is funded through equity, government grants and contracts from non-profit organizations, such as the Bill & Melinda Gates Foundation.

Business Documents

MG cp Summary

Patented production system (vivoXPRESS®) – The plant based production system produces high quality drugs at very low cost.

 

Unique glycosylation of drugs – Protein and antibody molecules often have carbohydrates (sugars) decorating the surface. PlantForm can create unique structures increasing the efficacy and reducing the dose such protein and antibody drugs.

 

Experienced management team – Veterans in the biotechnology industry having the experience to move the high-value PlantForm investment proposition forward.

PlantForm Corporation is a privately-held Canadian biopharmaceutical company, commercializing a plant-based manufacturing platform, vivoXPRESS®, for the low-cost production of high-value therapeutic drugs. Their pipeline includes biosimilar drugs with a focus on international markets including China, Europe, India, Latin America, MENA as well as major North American and European markets. The company is also developing innovator biologics for niche infectious disease and countermeasures-to-bioterrorism markets. Their pipeline is funded through equity, government grants and contracts from non-profit organizations, such as the Bill & Melinda Gates Foundation.

Don Stewart, CEO

Dr. Don Stewart, an entrepreneur and scientist, is a founder of PlantForm and assumes the roles of President and Chief Executive Officer.  Dr. Stewart brings 30 years’ management experience in the biotechnology industry to this role.  Dr. Stewart has founded and developed companies in the field of biotechnology and in real estate.

 

Ron Hosking, CFO

Mr. Ron Hosking, an experienced financial manager and chartered accountant, is a founder of PlantForm Corporation. Mr. Hosking brings 35 years of experience, providing strong leadership, sound business management and clear strategic financial direction to growing businesses in the life sciences industry.

 

David Cayea, COO

Mr. David Cayea is an entrepreneur who has successfully launched private-sector companies in multiple industries over the last 20 years.  Mr. Cayea joined PlantForm in 2011 as Director of International Relations & Business Development, responsible for advancing the Companies strategic growth strategy by developing and fostering global partnerships. More recently Mr Cayea was appointed to the expanded role of COO of PlantForm.


CardioComm Solutions, Inc.

CardioComm Solutions, Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

CardioComm Solutions, Inc.

Location: Toronto, Ontario 1
Sector: Life Science 1
1
Add to Shortlist
Express Interest

CardioComm Solutions, Inc. is a medical software company that specializes in developing solutions for mobile cardiac monitoring for the sports, medical and wellness markets. Specifically, they’re developing connectivity and integration solutions for ECG monitoring from wearable and holdable sensors to enable mobile monitoring of consumers or patients through medially credentialed (FDA, CE, Health Canada) compliant software solutions sold globally.

Business Documents

MG cp Summary
  • Has secured the software and device clearances for OTC class II medical device sales in Canada and the USA.
  • Has developed a SMART Monitoring ECG reading service for all HeartCheck™ branded/compatible devices.
  • Can leverage its experience securing medical device clearances to help consumer health device manufacturers get their products cleared.
  • Will have access to many devices without the cost and responsibility of developing and manufacturing.
  • Will facilitate sales of the devices through the sale of its GEMS based software and the device manufactures will facilitate the sale of CardioComm’s software through the sale of their devices outside of North America.

CardioComm Solutions,  Inc. is a medical software company that specializes in developing solutions for mobile cardiac monitoring for the sports, medical and wellness markets. Specifically, they’re developing connectivity and integration solutions for ECG monitoring from wearable and holdable sensors to enable mobile monitoring of consumers or patients through medially credentialed (FDA, CE, Health Canada) compliant software solutions sold globally.

Robert E. Caines, Chairman of the Board

Mr. Caines, Managing Partner / Founding Partner at Paley Advisors, is a serial entrepreneur and mergers and acquisitions executive with over thirty years of business startup, growth and management experience.  He founded Paley Advisors in 2014.  From 2002 to 2014.  He served as one of three Managing Partners at Paley Dixon, Inc., the New York City-based buy-side intermediary and advisory firm, founded in 1979.  There, he and partners Sarah Cooke and Richard Paley grew Paley Dixon into one of the top five buy-side intermediaries and advisory firms of its size in the US and Canada.  Previous to Paley Dixon, he held senior-level sales and sales management positions at Hummingbird, BrightStar, NetEra and ADP.  Previous to ADP.  Mr Caines and partners founded Cable Channels, Inc., the cable television electronic program guide software firm.  He currently serves as President and Founding Partner of a customized B2C/B2B cross-border shipping solutions provider, to be launched in Q2 2016.  He also serves as Treasurer and member of the Board of Directors of Kensington House Owner’s Corporation.  Mr. Caines previously served as Treasurer and member of the Board of Directors of the Salmagundi Club, as Treasurer and member of the Board of Directors of the Ali Forney Center and as a member of the Advisory Board of the Peccadillo Theatre Company.  He received a Master of Business Administration degree from the Thunderbird School of Global Management and a Bachelor of Architecture degree from the College of Engineering at the University of Notre Dame.

 

William E. Smith, Board Member

Mr. Smith began his career as a systems engineer at IBM Canada where he was sent to Japan in 1972 to provide IMS manufacturing expertise to Toyota.  In 1990, Mr. Smith underwent rigorous TV training in San Francisco and was live on CNN, Good Morning America and various live TV talk shows in Silicon Valley. He was invited in 1990 to be a keynote speaker at PAC Bell’s annual corporate convention where he spoke on the future of Home Automation technology. He was a guest speaker at Seybold’s first “Digital World” conference in Beverley Hills in 1991 where he spoke on the future of the digital highway and first proposed the revolutionary digital highway to Pac Bell and an audience of Silicon Valley high tech personalities.  Mr. Smith proudly describes how this was globally reported in Wired Magazine. As the founder of CardioComm Solutions in 1989, he is most pleased with his nomination as Canadian Entrepreneur of the Year in 1995.  Later in 2000 as Microsoft EMEA Finance Industry Manager, he traveled extensively throughout EMEA and been guest speaker at a large number of external conventions including : Abtec 2001, First Arab eBanking Summit, April 2001, Dubai, UAE, The European IT Banking Forum 2000, November 2000, Milan, Italy , Bank Tech New Era, November 2000, Cairo, Egypt, EBank 2000. Sept 2000, Dubai , 17th Asian Bankers Association General Meeting. Sept 2000, Istanbul , Themen für IDC- Branchenkonferenz Banken 2000.  Feb 2000, Vienna, EE/MENA CEO Summit, Feb 2000 London, FinanceSector.com – Christiana Bank, March 2000 Oslo By 2001 .  He was completing 2 years at Microsoft as EMEA Finance Industry Manager for Microsoft Europe, Middle East and Africa.  He left Microsoft in May 2001 to take the position of COO with ICT, a startup company focused on Core Banking opportunities in Financial Services.  In February 2004, Mr. Smith was invited by Royal Roads University of Canada to a life changing event – teaching a two week pre-MBA boot-camp course to 55 mature learners in Tehran, Iran.  Mr.Smith has always made an effort to understand the cultural issues of international business.  His training includes Intensive Spanish – Instituto Cervantes, London – October 2001 Survival Arabic – London University, School of Oriental and African Studies – March 2003 .  He is delighted to have been invited back CardioComm Solutions, Inc. as Director and to offer his contributions to the development of CardioComm Solutions, Inc. into a world class global cardiology company. 1

 

Etienne Grima, Chief Executive Officer

Mr. Grima has over twenty-two years of experience in basic and clinical research administration, business development and strengthening corporate performance.  Recognized for a unique and multidisciplinary approach to overseeing operational performance and fiscal resources, Mr. Grima joined the Board of Directors of CardioComm Solutions, Inc. in December of 2006. In January of 2008 he was requested to serve as the company’s Chief Financial Officer and Corporate Secretary during a period of organizational restructuring.  In May of 2010 he accepted the position of Chief Executive Officer.  Mr. Grima has also held the position of Chief Operating Officer and Financial Officer for the Canadian Heart Research Centre (CHRC) since its start in 1996 and a similar role in MD Primer Inc. since 2004.  In all his roles, Mr. Grima continues to oversee operational and financial performance, contract and budget negotiations, finance reporting and the evaluation of strategic partnerships and long term growth opportunities. Prior to the CHRC, Mr. Grima managed the St. Michael’s Hospital (SMH) Health Sciences Research Centre in Toronto.  He guided SMH to become the fastest growing University of Toronto affiliated research center between 1994 and1997, acting as the signing officer on 350 externally funded clinical and basic research budgets, and overseeing the design, construction and maintenance of 27,000 square feet of clinical and basic research laboratories.  During his tenure, he developed a detailed understanding and methodology of the successful performance of clinical research within a hospital environment and became a member and Accredited Health Science Executive of the Canadian College of Health Service Executives.  His educational background was rooted in his persistent interest in biology and he completed his academic career with an emphasis on human physiology, toxicology and zoology graduating from University of Toronto with high distinction in 1984.  He completed his graduate studies in 1986 with a Masters degree from the Faculty of Medicine, Department of Physiology, Centre for Research in Neurodegenerative and served as a peer reviewer for research publications and grant applications. 1 1